Lucid Diagnostics (NASDAQ:LUCD) Announces Quarterly Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) issued its earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06), Zacks reports.

Lucid Diagnostics Price Performance

LUCD stock opened at $1.48 on Monday. The business has a fifty day moving average price of $1.20 and a 200 day moving average price of $0.98. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63. The stock has a market capitalization of $87.83 million, a price-to-earnings ratio of -1.29 and a beta of 1.34.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets lowered their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $3.63.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.